Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales

Dow Jones05-02

By Denny Jacob

Regeneron Pharmaceuticals posted lower-than-expected revenue in its latest quarter which resulted in part from lower sales of EYLEA in the U.S.

The biotechnology company recorded net income of $722 million, or $6.27 a share, for the first quarter ended March 31, down from $817.8 million, or $7.17 a share, a year earlier. Adjusted earnings were $9.55 a share, below analysts' estimates of $10.17 a share.

Revenue ticked down to $3.15 billion from $3.16 billion. Analysts polled by FactSet expected $3.23 billion.

Sales of EYLEA in the U.S. decreased in the first quarter compared with the prior-year period, which Regeneron attributed primarily to changing market dynamics that resulted in lower volumes and a lower net selling price.

"We had a strong quarter of EYLEA HD uptake, and we are well positioned to continue our leadership in retinal diseases," said Chief Executive Leonard Schleifer.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

May 02, 2024 06:47 ET (10:47 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432673285?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-02 18:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2432673285","market":"other","top_or_hot":-1,"title":"Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Denny Jacob \n</p>\n<p>\n  Regeneron Pharmaceuticals posted lower-than-expected revenue in its latest quarter which resulted in part from lower sales of EYLEA in the U.S. \n</p>\n<p>\n  The biotechnology company recorded net income of $722 million, or $6.27 a share, for the first quarter ended March 31, down from $817.8 million, or $7.17 a share, a year earlier. Adjusted earnings were $9.55 a share, below analysts' estimates of $10.17 a share. \n</p>\n<p>\n  Revenue ticked down to $3.15 billion from $3.16 billion. Analysts polled by FactSet expected $3.23 billion. \n</p>\n<p>\n  Sales of EYLEA in the U.S. decreased in the first quarter compared with the prior-year period, which Regeneron attributed primarily to changing market dynamics that resulted in lower volumes and a lower net selling price. \n</p>\n<p>\n  \"We had a strong quarter of EYLEA HD uptake, and we are well positioned to continue our leadership in retinal diseases,\" said Chief Executive Leonard Schleifer. \n</p>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 02, 2024 06:47 ET (10:47 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-02 18:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Denny Jacob \n\n\n  Regeneron Pharmaceuticals posted lower-than-expected revenue in its latest quarter which resulted in part from lower sales of EYLEA in the U.S. \n\n\n  The biotechnology company ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REGN","symbol_name":"再生元制药公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2432673285","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432673285","pubTimestamp":1714646820,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Regeneron Pharmaceuticals posted lower-than-expected revenue in its latest quarter which resulted in part from lower sales of EYLEA in the U.S.The biotechnology company recorded net income of $722 million, or $6.27 a share, for the first quarter ended March 31, down from $817.8 million, or $7.17 a share, a year earlier. Adjusted earnings were $9.55 a share, below analysts' estimates of $10.17 a share.Revenue ticked down to $3.15 billion from $3.16 billion. Analysts polled by FactSet expected $3.23 billion.Sales of EYLEA in the U.S. decreased in the first quarter compared with the prior-year period, which Regeneron attributed primarily to changing market dynamics that resulted in lower volumes and a lower net selling price.\"We had a strong quarter of EYLEA HD uptake, and we are well positioned to continue our leadership in retinal diseases,\" said Chief Executive Leonard Schleifer.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"REGN":"再生元制药公司"},"translate_title":"由于EYLEA销售额下降，再生元制药1Q收入下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1},"content_text":"By Denny Jacob \n\n\n  Regeneron Pharmaceuticals posted lower-than-expected revenue in its latest quarter which resulted in part from lower sales of EYLEA in the U.S. \n\n\n  The biotechnology company recorded net income of $722 million, or $6.27 a share, for the first quarter ended March 31, down from $817.8 million, or $7.17 a share, a year earlier. Adjusted earnings were $9.55 a share, below analysts' estimates of $10.17 a share. \n\n\n  Revenue ticked down to $3.15 billion from $3.16 billion. Analysts polled by FactSet expected $3.23 billion. \n\n\n  Sales of EYLEA in the U.S. decreased in the first quarter compared with the prior-year period, which Regeneron attributed primarily to changing market dynamics that resulted in lower volumes and a lower net selling price. \n\n\n  \"We had a strong quarter of EYLEA HD uptake, and we are well positioned to continue our leadership in retinal diseases,\" said Chief Executive Leonard Schleifer. \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 02, 2024 06:47 ET (10:47 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432673285"}